RECRUITING

Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma

Longitudinal Follow-Up of Retinopathy and Opticopathy After Treatment With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma

NCT06280040•Medical University of Vienna

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the incidence and severity of retinopathy and opticopathy one year after treatment with hypofractionated stereotactic photon radiotherapy due to uveal melanoma. Patients will be imaged before radiation, as well as 3, 6, 9 and 12 months after radiation using sonography funds photography, optical coherence tomography angiography, oximeter and microperimetry.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with newly diagnosed uveal melanoma, who will be treated with hypofractionated stereotactic photon radiotherapy as part of clinical routine.

Exclusion Criteria

•unwillingness to participate in the study
•severe media opacity

Locations (1)

Department of Ophthalmology and Optometry, Medical University Vienna

Vienna, Austria

Key Dates

Start Date

November 23, 2023

Primary Completion Date

June 30, 2025

Completion Date

June 30, 2025

Last Updated

March 6, 2024

Enrollment

20

ESTIMATED participants

Conditions

Uveal Melanoma

Interventions

Clinical examination and multimodal ocular imaging

DIAGNOSTIC_TEST

Contacts

Judith Kreminger, MD

CONTACT

0043 1 40400 48470 judith.kreminger@meduniwien.ac.at

Reinhard Told, MD, PhD

CONTACT

0043 1 40400 48470 reinhard.told@meduniwien.ac.at

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690

Choroidal MelanomaIndeterminate Lesions+2 more

View study

RECRUITINGPHASE2/PHASE3

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406

Metastatic Uveal Melanoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGPHASE1